Concepedia

Matthew Guo

MG

Statistics

Publications

28

Citations

11.6K

H-Index

24

Active since

1998

Affiliations

Eisai (United States)(Current)

Amgen (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Oregon Health & Science University

University of Pennsylvania

Matthew Guo is an author at Eisai (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

1998–2019

28

Publications

28

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

, , +12

Chemoradiotherapy of Locally Advanced Esophageal Cancer

Jay S. Cooper, Matthew Guo, Arnold Herskovic et al. · JAMA · 1999 · 2K citations

, , +16

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet · 2016 · 766 citations · Full text

, , +12

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Vicky Makker, Drew Rasco, Nicholas J. Vogelzang et al. · The Lancet Oncology · 2019 · 480 citations · Full text

, , +6

Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism

Munro Peacock, John P. Bilezikian, Preston Klassen et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 464 citations · Full text

, , +17

1–5 of 28